Akèy › Kansè pankreyas › Texas › Houston
Etid klinik pou Kansè pankreyas nan Houston, TX
61 etid pou Kansè pankreyas ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Houston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Houston
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- Houston Methodist Hospital, Houston
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Ap rekriteFaz 3
- Investigative Site US011, Houston
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Ap rekriteFaz 3
- Houston Methodist Office of Graduate - Houston Methodist Neal Cancer Center at Texas Medical Center, Houston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- Baylor College of Medicine, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Ap rekriteEtid obsèvasyon
- The University of Texas MD Anderson Cancer Center, Houston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0085, Houston
CREO - Microwave Ablation Feasibility Study
Ap rekrite
- Memorial Hermann-Texas Medical Center, Houston
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
- Texas Children's Hospital, Houston
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson, Houston
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Ap rekriteEtid obsèvasyon
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas - MD Anderson Cancer Center, Houston
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Ap rekriteFaz 1
- MDACC, Houston
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Ap rekrite
- Texas Oncology, Houston
- Baylor College of Medicine, Houston
- University Cancer and Diagnostic, Houston
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Ap rekriteFaz 1
- Baylor College of Medicine Medical Center - McNair Campus, Houston
- Baylor St. Lukes Medical Center, Houston
- Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Ap rekriteFaz 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- Houston Methodist Hospital, Houston
- ak 4 plis
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Ap rekriteFaz 1/2
- Oncology Consultants, P.A., Houston
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 1
- Excel Diagnostics & Nuclear Oncology Center, Houston
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Ap rekriteFaz 2
- Baylor College of Medicine, Houston
- Baylor St. Luke's Medical Center (BSLMC)., Houston
- Houston Methodist Hospital, Houston
Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions
Ap rekriteEtid obsèvasyon
- The University of Texas Health Science Center at Houston, Houston
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
Ap rekrite
- M D Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Houston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- University of Texas, MD Anderson Cancer Center, Houston
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Ap rekrite
- M D Anderson Cancer Center, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Ap rekriteEtid obsèvasyon
- Md Anderson Cancer Center, Houston
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ap rekriteFaz 2
- Ohio State University-Telemedicine, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #1, Houston
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Ap rekriteEtid obsèvasyon
- Baylor College of Medicine, Houston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Etid Kansè pankreyas nan lòt vil
- New York City, NY60 etid
- Boston, MA43 etid
- Nashville, TN39 etid
- Los Angeles, CA35 etid
- St. Louis, MO33 etid
- Arlington, VA33 etid
- Baltimore, MD31 etid
- San Antonio, TX31 etid
- Philadelphia, PA26 etid
- Tampa, FL26 etid
- Durham, NC24 etid
- San Diego, CA24 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Melanom59 etid
- Karsinòm selil skuamèz tèt ak kou47 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.